HSV1-hGM-CSF联合阿霉素治疗小鼠乳腺癌模型的疗效
该研究在体外评估HSV1-hGM-CSF与阿霉素对小鼠乳腺癌4T1细胞的杀伤作用,并建立荷瘤小鼠模型比较单药与联合治疗对肿瘤生长和生存期的影响。结果显示两药均显著抑制肿瘤生长并延长生存期,联合治疗具有协同抗肿瘤效应。
要点
- HSV1-hGM-CSF与阿霉素均显著抑制4T1细胞增殖并缩小荷瘤小鼠原发肿瘤体积(P<0.001)。
- 阿霉素诱导4T1细胞G2/M期阻滞,HSV1-hGM-CSF杀伤不依赖细胞周期。
- 阿霉素联合HSV1-hGM-CSF较单药进一步缩小肿瘤并延长中位生存时间。
核心结论
- 溶瘤病毒HSV1-hGM-CSF联合阿霉素治疗小鼠乳腺癌具有协同抗肿瘤效应。
研究设计与样本
- 体外以不同MOI(0、0.5、1、2)HSV1-hGM-CSF和不同浓度(0、2、4、8 μg/ml)阿霉素处理4T1细胞。
- 建立乳腺癌荷瘤小鼠模型,观察肿瘤生长、生存时间和毒副反应。
主要发现
- 治疗后16 d,阿霉素联合高剂量HSV1-hGM-CSF组肿瘤体积为(144.40±27.68)mm³,联合低剂量组为(216.80±57.18)mm³。
- 阿霉素组、高剂量HSV1-hGM-CSF组、低剂量HSV1-hGM-CSF组和对照组肿瘤体积分别为(246.10±21.90)mm³、(327.50±44.24)mm³、(213.30±32.31)mm³和(495.80±75.87)mm³。
- 与对照组比较,阿霉素或HSV1-hGM-CSF治疗均明显缩小原发肿瘤体积(P<0.001)。
- 上述六组中位生存时间分别为48、50、40、42、43和37 d;阿霉素组、高剂量及低剂量HSV1-hGM-CSF组均较对照组明显延长(P<0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the oncolytic effect of herpes simplex virus type 1 which carried recombined human granulocyte-macrophage colony-stimulating factor (HSV1-hGM-CSF) on the mouse breast cancer cell line 4T1 and compare the anticancer effects of HSV1-hGM-CSF, doxorubicin alone or combination on the breast cancer in mice. Methods: We investigated the cytotoxic effect on 4T1 cells in vitro, the cell growth, cell apoptosis and cell cycle of 4T1 cells treated with oncolytic HSV1-hGM-CSF at different MOIs (0, 0.5, 1 and 2) and doxorubicin at different concentrations (0, 2, 4 and 8 μg/ml). The effects of oncolytic HSV1-hGM-CSF and doxorubicin on the tumor growth, survival time and their side effects on the mouse breast cancer model were observed. Results: Both oncolytic HSV1-hGM-CSF and doxorubicin significantly inhibited the proliferation of 4T1 cells in vitro. Doxorubicin induced the G(2)/M phase arrest of 4T1 cells, while the cytotoxicity of oncolytic HSV1-hGM-CSF was no cell cycle-dependent.At day 16 after treatment with doxorubicin and HSV1-hGM-CSF, the tumor volume of 4T1 tumor bearing mice were (144.40±27.68)mm(3,) (216.80±57.18)mm(3,) (246.10±21.90)mm(3,) (327.50±44.24)mm(3,) (213.30±32.31)mm(3) and (495.80±75.87)mm(3) in the groups of doxorubicin combined with high dose HSV1-hGM-CSF, doxorubicin combined with low dose HSV1-hGM-CSF, doxorubicin alone, high dose HSV1-hGM-CSF alone, low dose HSV1-hGM-CSF alone and control, respectively.Compared with the control group, both doxorubicin and HSV1-hGM-CSF treatment exhibited significant reduction of primary tumor volume in vivo (P<0.001). The median survival times were 48, 50, 40, 42, 43 and 37 days in the six groups mentioned above, respectively. The median survival period of doxorubicin alone, high dose HSV1-hGM-CSF alone and low dose HSV1-hGM-CSF alone were significantly longer than that of control (P<0.05). Conclusion: Synergistic effect of sequential treatment with doxorubicin and oncolytic HSV1-hGM-CSF is observed in 4T1 mouse breast cancer. 目的: 评价携带重组人粒细胞巨噬细胞集落刺激因子的溶瘤性1型单纯疱疹病毒(HSV1-hGM-CSF)对小鼠乳腺癌细胞系4T1的溶瘤作用,比较HSV1-hGM-CSF和阿霉素单药或联合使用治疗小鼠乳腺癌的效果。 方法: 以不同感染复数(0、0.5、1和2)的HSV1-hGM-CSF和不同浓度(0、2、4和8 μg/ml)的阿霉素处理4T1细胞,观察HSV1-hGM-CSF和阿霉素在体外对4T1细胞的杀伤作用,以及对4T1细胞增殖、凋亡和细胞周期的影响。建立乳腺癌荷瘤小鼠模型,观察HSV1-hGM-CSF和阿霉素对荷瘤小鼠肿瘤生长、生存时间和毒副反应的影响。 结果: 溶瘤病毒HSV1-hGM-CSF和阿霉素在体外均可以有效杀伤4T1细胞,可以明显抑制4T1细胞的增殖,阿霉素对4T1细胞细胞周期的影响主要表现为G(2)/M期阻滞,而HSV1-hGM-CSF可以均一性杀伤各细胞周期的细胞。荷瘤小鼠经阿霉素和HSV1-hGM-CSF治疗后16 d,阿霉素+高剂量HSV1-hGM-CSF组、阿霉素+低剂量HSV1-hGM-CSF组、阿霉素组、高剂量HSV1-hGM-CSF组、低剂量HSV1-hGM-CSF组和对照组荷瘤小鼠的肿瘤体积分别为(144.40±27.68)mm(3)、(216.80±57.18)mm(3)、(246.10±21.90)mm(3)、(327.50±44.24)mm(3)、(213.30±32.31)mm(3)和(495.8±75.87)mm(3)。与对照组比较,无论是阿霉素治疗还是HSV1-hGM-CSF治疗,均可以明显缩小荷瘤小鼠的原发肿瘤体积(P<0.001)。阿霉素+高剂量HSV1-hGM-CSF组、阿霉素+低剂量HSV1-hGM-CSF组、阿霉素组、高剂量HSV1-hGM-CSF组、低剂量HSV1-hGM-CSF组和对照组荷瘤小鼠的中位生存时间分别为48、50、40、42、43和37 d。与对照组比较,阿霉素组、高剂量HSV1-hGM-CSF组和低剂量HSV1-hGM-CSF组荷瘤小鼠的中位生存时间均明显延长(P<0.05)。 结论: 溶瘤病毒HSV1-hGM-CSF联合阿霉素治疗小鼠乳腺癌具有协同抗肿瘤效应。.
引用
- Zhuang XF, Zhang SR, Liu BL, et al. [The therapeutic effect of HSV1-hGM-CSF combined with doxorubicin on the mouse breast cancer model]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29575835. doi:10.3760/cma.j.issn.0253-3766.2018.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。